A recent ruling by the 5th U.S. Circuit Court of Appeals has restricted the distribution of mifepristone, a medication used for early pregnancy termination and miscarriage management, to in-person dispensing at clinics. This decision blocks the mailing of prescriptions, significantly impacting telemedicine abortion services that have expanded since the Supreme Court overturned Roe v. Wade in 2022. Mifepristone works by blocking the hormone progesterone, essential for maintaining pregnancy, and is typically followed by another medication to complete the abortion process. The ruling stems from a legal challenge involving Louisiana's attorney general, who argued that current FDA regulations undermine state abortion bans. The court's decision raises critical questions about the intersection of state policies and federal drug regulations. Advocates warn that this restriction will disproportionately affect marginalized communities, making access to reproductive healthcare more difficult. As the FDA conducts a review of mifepristone's safety, the ruling may set the stage for further legal battles, potentially reaching the Supreme Court again.